微创医疗（00853）今日盘中大涨6.15%，引发市场广泛关注。该股价上涨主要受益于上海生物医药并购基金的战略入股。
据悉，上海生物医药并购基金拟通过协议转让方式收购Otsuka Medical Devices Co., Ltd.持有的微创医疗1.35亿股份，成为微创医疗的战略股东。按微创医疗此前收盘价10.94港元/股估算，该笔交易市场价值约在14亿~15亿港元。这一举措被视为国家队对医疗器械行业的重要支持。
微创医疗作为国产创新医疗器械龙头公司，业务已拓展至心律管理、骨科、心血管介入等多个领域，拥有6家A股及港股上市公司。上海生物医药并购基金表示，将依托国资背景和产业资源，持续关注微创医疗的发展需求，助力其核心业务拓展及潜在战略并购。这一战略合作预计将为微创医疗带来更多发展机遇，推动公司在创新和规模扩张方面取得进一步突破。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.